These studies collectively reinforce the utility of PSMA-PET in prostate cancer management, though the differing focuses on specific PET parameters (e.g., SUVmax vs. PSMA-TLU) suggest that a more comprehensive approach incorporating multiple PSMA-PET metrics could enhance prognostic accuracy. This evidence concerns the gene FOLH1 and Familial prostate cancer.